April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Adalimumab In Juvenile Idiopathic Arthritis-associated Uveitis : A Retrospective Monocentric Study Of 18 Children
Author Affiliations & Notes
  • Neil Abi-Ayad
    Ophthalmology department, Pitié-Salpêtrière hospital, Paris, France
  • Pierre Quartier
    unité d'immuno-hématologie et rhumatologie pédiatrique, Paris, France
  • Celine Terrada
    Ophthalmology department, Pitié-salpêtrière hospital, Paris, France
  • Christine Fardeau
    Ophthalmology department, Pitié Salpêtrière Hospital, Paris, France
  • Nathalie Cassoux
    Ophthalmology department, Pitié-salpêtrière hospital, Paris, France
  • Phuc Lehoang
    Ophthalmology department, Hôpital Pitié-Salpêtrière hospital, Paris, France
  • Bahram Bodaghi
    Ophthalmology department, Hôpital Pitié-Salpêtrière hospital, Paris, France
  • Footnotes
    Commercial Relationships  Neil Abi-Ayad, None; Pierre Quartier, None; Celine Terrada, None; Christine Fardeau, None; Nathalie Cassoux, None; Phuc Lehoang, None; Bahram Bodaghi, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 6566. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Neil Abi-Ayad, Pierre Quartier, Celine Terrada, Christine Fardeau, Nathalie Cassoux, Phuc Lehoang, Bahram Bodaghi; Adalimumab In Juvenile Idiopathic Arthritis-associated Uveitis : A Retrospective Monocentric Study Of 18 Children. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6566.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate adalimumab in severe juvenile idiopathic arthritis (JIA)-associated uveitis

Methods: : We retrospectively analysed 18 children with severe JIA-associated uveitis, who were treated with adalimumab (20 or 40-mg, every two weeks) when the previous immunosuppressive therapy had been ineffective. It consisted of systemic steroids (n=18), methotrexate (n=18), azathioprine (n=8), mycophenolate mofetil (n=1), infliximab (n=5), etanercept (n=5). Primary outcome was to assess decreasing in laser flare photometry values 3 months after adalimumab therapy. Clinical features (Standardization of Uveitis Nomenclature criteria, vitreous haze, macular edema and papillitis) and oral prednisone threshold were also considered.

Results: : Median age was 5.7 years (range 1-16) and sex ratio (F/M) was 3.5. Median duration before adalimumab therapy was 82.6 months (range 16-262). Median laser flare photometry value at 3 months was significantly reduced from 149.5 ph/ms (range 24-335) to 71.5 ph/ms (range 8-164) (p<0.03). During a mean follow-up of 18.4 months (range 3-60), median oral prednisone decreased from 10 mg/day (range 0-20) to 5.25 mg/day (range 0-20). Uveitis was controlled in 13 cases (72.2%). Relapses occurred in two cases (11.1%) and adalimumab was ineffective in three cases (16.7%). Two children (11.1%) discontinued the treatment : one because of intolerance with allergic reaction, and one because of neurologic side-effects.

Conclusions: : Adalimumab is efficient to control uveitis and seems to have a steroid-sparing effect. Laser flare photometry provides an objective improvement of intraocular inflammation at 3 months of treatment in most of severe cases.

Keywords: inflammation • uveitis-clinical/animal model • immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×